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Abstract. The mitochondrial voltage-dependent anion channel 1 (VDAC1) is involved in the release of apoptotic proteins with
possible relevance in Alzheimer’s disease (AD) neuropathology. Through proteomic analysis followed by Western blotting
and immunohistochemical techniques, we have found that VDAC1 is overexpressed in the hippocampus from amyloidogenic
AD transgenic mice models. VDAC1 was also overexpressed in postmortem brain tissue from AD patients at an advanced
stage of the disease. Interestingly, amyloid- (A) soluble oligomers were able to induce upregulation of VDAC1 in a human
neuroblastoma cell line, further supporting a correlation between A levels and VDAC1 expression. In hippocampal extracts
from transgenic mice, a significant increase was observed in the levels of VDAC1 phosphorylated at an epitope that is susceptible
to phosphorylation by glycogen synthase kinase-3, whose activity was also increased. The levels of hexokinase I (HXKI), which
interacts with VDAC1 and affects its function, were decreased in mitochondrial samples from AD models. Since phospho-VDAC
and reduced HXKI levels favors a VDAC1 conformational state more prone to the release proapoptotic factors, regulation of the
function of this channel may be a promising therapeutic approach to combat AD.
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INTRODUCTION
Alzheimer’s disease (AD), the main cause of
dementia among the aged people, is character-
ized by several neuropathological hallmarks, such
as amyloid- peptide (A) enriched extracellular
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plaques, hyperphosphorylated tau-containing intracel-
lular neurofibrillary tangles (NFT), and substantial loss
of synapses and neurons [1]. Although the exact cause
of AD is unknown, multiple lines of evidence implicate
A as the agent initiating the cascade of pathologi-
cal events in all cases of AD [2]. The mutations in
three genes [amyloid -protein precursor (APP) and
presenilins 1 and 2] linked to familial forms of the dis-
ease (fAD) have been shown to increase the production
and/or deposition of A in the brain (reviewed in [3]).
On this basis, transgenic mice overexpressing mutant
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genes linked to fAD are the most used animal models
to study AD. These transgenic mice exhibit a range of
AD-like molecular and cognitive alterations, including
deficits in learning and memory, amyloid deposits, and
gliosis (reviewed in [4]). The Tg2576 mouse express-
ing the human Swedish mutation is one of the best
characterized lines of APP transgenic animals [5–7].
In this mouse, exponential accumulation of A peptide
in the brain starts between 7 and 12 months of age, and
amyloid deposits and impaired memory in the water
maze test appear at the age of 9–11 months [6, 8, 9].
Several studies have demonstrated a direct dele-
terious effect of A on mitochondrial structure and
function (reviewed in [10]). Addition of A to mouse
brain mitochondria induces cytochrome c release and
mitochondrial swelling. Furthermore, A accumulates
in mitochondria in AD affected neurons and disturbs
the balance of fission/fusion and mitochondrial move-
ment dynamics [11, 12].
Voltage-dependent anion channel 1 (VDAC1),
a major constituent of the outer mitochondrial mem-
brane, is part of the mitochondrial permeability transi-
tion pore (MPTP) forming in the outer mitochondrial
membrane a voltage-gated pore, which is important
for passive diffusion of substances through the mem-
brane. Three isoforms of VDAC (VDAC 1–3) have
been found in humans and in different animal species
[13]. Significantly, it has been shown that VDAC1 can
assume a configuration that promotes the release of
proapoptotic factors, such as cytochrome c [14]. Mito-
chondrial VDAC-inmunoreactive structures consistent
with mitochondrial accumulation occurs in the dys-
trophic neurites of A plaques in AD [15].
On this basis, and given the relationship between A
and mitochondrial dysfunction, we decided to analyze
the amount and the activity of VDAC1 in Tg2576 mice
at different ages. An increase in VDAC1 protein in
mice with high levels of Awas detected. Augmented
levels of VDAC1 were also found in postmortem brain
tissue from AD patients at an advanced stage of the dis-
ease. Addition of A soluble oligomers to SH-SY5Y
cell cultures also led to increased levels of total VDAC1
suggesting a role of Apeptide in VDAC1 increase and
phosphorylation which could facilitate the leakage of
mitochondrial proapoptotic molecules.
MATERIALS AND METHODS
Animals
The Tg2576 line express the human 695-aa iso-
form of APP containing the Swedish double mutation
(hAPPSwe) [(APP695) Lys670-Asn, Met671-Leu]
driven by the hamster prion promoter. In this line, the
A-peptide content in the brain accumulates exponen-
tially between 7 and 12 months of age [6].
Line J20 produces the human 770-aa APP carrying
the Swedish and Indiana (Val717Phe) fAD mutations
under control of the platelet-derived growth factor
(PDGF) promoter. In this mice levels of A are sig-
nificantly increased by the age of 4 months [16]. In all
cases, results were compared with those obtained in
non-transgenic littermates.
Mice were housed in a temperature-controlled room
under a 12 h light/dark cycle with free access to
food and water. Animal experimentation received the
approval from the Ethical Committee of the Univer-
sity of Navarra, and was performed in accordance with
the European Council Directive 86/609/CEE on Pro-
tection of Animals Used for Experimental and Other
Scientific Purposes.
2D-electrophoresis
Iso-electric focusing (IEF) dimension
For IEF, samples of 800g of proteins were solu-
bilized in 300l of rehydration solution [9.5 M urea,
4% (w/v) CHAPS, 1% (w/v) dithiothreitol, 0.5% Bio-
Lyte 3–10 and bromophenol blue]. This mixture of
sample-containing rehydration solution was applied
in the strip holder channel. The solubilized proteins
were loaded onto an immobilized linear pH gradi-
ent (IPG) strip, pH 5–8, 17 cm (Bio-Rad, CA, USA).
Therefore, the IPG strips were lowered, gel side down,
onto the rehydration solution, and overlayered with
mineral oil. Iso-electric focusing was performed on a
Protean IEF Cell (Bio-Rad, CA, USA) at 20◦C as fol-
lows: 12–16 h at 50 V, 1 h at 200 V, 1 h at 500 V, 1 h
at 1000 V, 30 min at 1000–8000 V, and 7 h at 8000 V.
The strips were focused for a total of 60,000 V h.
After IEF, the strips were equilibrated for two inter-
vals of 5 min in equilibration buffer containing 6 M
urea, 0.375 M Tris–HCl, 2% SDS, and 20% glycerol,
pH 8.8. For the first equilibration step, we added dithio-
threitol (2% w/v) to reduce the proteins. Thereafter the
proteins were carbamidomethylated with 2.5% (w/v)
iodoacetamide.
Second dimension electrophoresis
SDS–PAGE was performed on a vertical elec-
trophoresis system. The equilibrated IPG strip was
placed on top of a SDS-polyacrylamide gel (12.5%
T; 2.6% C) (Bio-Rad, CA, USA) and sealed with low
melting point agarose. Electrophoresis was carried out
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at 20◦C on a Protean xi Cell (Bio-Rad, CA, USA)
using a two-phase program. The first phase was set
at 85 V for 12 h and the second phase was set at 300 V
for 1 h.
The proteins of the 2D-gels obtained were detected
using a colloidal Coomassie G-250 staining (Bio-Rad,
CA, USA). The stained gels were digitized with a
GS-800 calibrated densitometer (Bio-Rad, CA, USA)
and analyzed with the Discovery Series PDQuest 2-D
software (Bio-Rad, CA, USA). Qualitative and quan-
titative differences were detected and only the spots
of which the integrated intensity differed by a fac-
tor of 1.5 minimum and occurring on all gels were
accepted.
Identiﬁcation of proteins by mass spectrometry
The identification of proteins was realized at the
proteomics unit of the Center for Applied Medical
Research (CIMA) under the direction of Dr. Fernando
J. Corrales. Gel spots corresponding to proteins dif-
ferentially expressed were collected manually and
processed on a MassPrep station from Micromass
(Manchester, UK). Gel specimens were de-stained
with 50 mM ammonium bicarbonate/50% (vol/vol)
acetonitrile. Then, proteins were reduced with 10 mM
DTT in 100 mM ammonium bicarbonate and alky-
lated with 55 mM iodoacetamide in the same buffer.
In-gel protein digestion was performed with 6 ng/l
trypsin in 50 mM ammonium bicarbonate for 5 h at
37◦C. The resulting peptides were extracted with 1%
(vol/vol) formic acid/2% (vol/vol) acetonitrile. Finally,
2l samples were mixed with 2l of a saturated
solution of -cyano-4-hydroxy-transcinnamic acid in
trifluoroacetic acid 0.1%/50% (vol/vol) acetonitrile
and spotted into a matrix-assisted laser desorption
ionization (MALDI) target plate. Tryptic peptides
were then analyzed on a MALDI-time-of-flight (TOF)
GL-REF mass spectrometer (Micromass, Manchester,
UK). Data processing was performed with MASS-
LYNX. Database searching (Swiss-Prot, TrEMBL,
Ensembl) to identify proteins of interest from their pep-
tide fingerprint, was performed with PROTEINLYNX
GLOBAL SERVER (Micromass, Manchester, UK).
Preparation of Amyloid-β-Derived Diffusible
Ligands (ADDLs)
ADDLs were prepared with synthetic A1-42
(Bachem, CA, USA) according to the procedure
described previously [17]. In brief, the peptide was
dissolved in 1,1,1,3,3,3,-hexafluoro-2-propanol (HFP)
to 1 mM and incubated for 1 h at room temperature
and 5 min on ice. The peptide was stored as a dried
film at –80◦C after evaporation of the HFP. The day
before use, dried peptide was resuspended in DMSO
anhydrous to a final concentration of 5 mM, sonicated
for 10 min, and diluted with ice-cooled phenol red-
free Ham’s F-12 (Invitrogen, CA, USA) to 100M and
placed at ◦C for 24 h to form ADDLs. Before adding to
cells, oligomers solution was centrifuged at 14000×g
for 10 min and the supernatant was used. An aliquot of
this preparation was analyzed qualitatively by Western
blotting (Fig. 5A).
SH-SY5Y cell cultures
The SH-SY5Y cell line was obtained from ATCC
(CRL-2266) [18]. The cells were grown up to 90% con-
fluence at 37◦C and 5% CO2 atmosphere in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 (Gibco,
Invitrogen, CA, USA) supplemented with 10% fetal
bovine serum (FBS) on 60 mm plates (Corning, MA,
USA). Before treatment ADDL solution was dissolved
up to a 5M in DMEM/F12 without FBS and added
to cells for the indicated times.
Human AD samples and controls
A total of 9 individuals from the Thomas Willis
Oxford Brain Collection were included in the study,
5 patients with clinical diagnosis of dementia, and 4
elderly normal controls. Those patients with demen-
tia were an autopsied subset of subjects included in a
prospective study of behavioral changes in clinically
diagnosed as demented patients [19]. Diagnoses were
made using Cambridge Mental Disorders of the Elderly
Examination (CAMDEX) [20], DMS-III-R criteria
[21], and NINCDS-ADRA criteria [22]. Cognitive
status was assessed using the Mini-Mental State Exam-
ination (MMSE) [23]. All tissues from control patients
were examined by a pathologist and were confirmed to
be free of gross neuropathology; clinical information
indicated no gross neurological or psychiatric disorder.
For all subjects, informed consent had been obtained
from relatives before the removal of brain tissue at
death and subsequent use of the material for research.
The study had Local Ethics Committee’s approval. At
autopsy, brains were removed and blocks correspond-
ing to frontal (Brodmann area 10, BA10) cortex were
stored at –80◦C until processing. All patients were
found to meet CERAD criteria [24] for a diagnosis
of AD, and all brains were Braak stage V or VI as
assessed by a neuropathologist.
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Production of protein extracts
Mice were killed by cervical dislocation and hip-
pocampi were quickly dissected from the brains.
Total tissue homogenates were obtained by homog-
enizing the hippocampus in ice-cold RIPA buffer
[50 mM Tris–HCl pH 7.4, 0.25% sodium deoxico-
late, 1% Nonidet P-40 (Roche Diagnostics, Mannheim,
Germany), 150 mM NaCl, 1 mM EDTA, protease
inhibitors (CompleteTM Protease inhibitor cocktail,
Roche Diagnostics, Mannheim, Germany), and phos-
phatase inhibitors (1 mM Na3VO4, 1 mM NaF)].
The homogenates were sonicated for 10 s, incu-
bated on ice 30 min and centrifuged at 19000×g for
20 min at 4◦C. Protein concentration was determined
(Bradford protein assay, Bio-Rad, CA, USA) and
aliquots were stored at –80◦C until used. To obtain
protein homogenates from SH-SY5Y, cells were lysed
in 100l of RIPA buffer and the same protocol as was
followed.
Western blotting
For Western blot analysis, samples were mixed
with an equal volume of 2X Laemmli sample buffer,
resolved onto SDS-polyacrylamide gels and trans-
ferred to nitrocellulose membrane (Hybond ECL,
Amersham Biosciences, UK). The membranes were
blocked with 5% milk, 0.05% Tween-20 in PBS
or TBS followed by overnight incubation with the
following primary antibodies: goat polyclonal anti-
VDAC1 [for mouse samples (1 : 200, Santa Cruz
Biotechnology, Inc., CA, USA)], Anti-VDAC1 Rab-
bit pAb [for human samples (1/1000, Calbiochem,
Merck Chemicals Ltd., Nottingham, UK)], rabbit
polyclonal anti-phospho-glycogen synthase kinase-3
(GSK3) Ser9 (1 : 000, Cell Signalling Technol-
ogy, MA, USA), rabbit polyclonal anti-GSK3
(1 : 000, Santa Cruz Biotechnology, CA, USA), rab-
bit polyclonal anti-phospho-Akt Ser473 (1 : 1000, Cell
Signalling Technology, MA, USA), goat polyclonal
anti-Hexokinase I (1 : 500, Santa Cruz Biotechnology,
CA, USA), rabbit polyclonal anti-phophothreonine
(1 : 1000, Zymed laboratories, CA, USA), and goat
polyclonal anti-Actin (1 : 10000, Santa Cruz Biotech-
nology, CA, USA).
For qualitative analysis of ADDL, an aliquot of
the preparation were mixed with XTTM sample buffer
(Bio-Rad, CA, USA). Oligomers were separated in
a CriterionTM precast Bis-Tris 4–12% gradient (Bio-
Rad, CA, USA) and transferred to a PVDF membrane
with 0.2m removal rating (Hybond LFP, Amersham
Biosciences, UK). The membranes were blocked with
5% milk, 0.05% Tween-20 in TBS followed by
overnight incubation with the mouse monoclonal 6E10
antibody (1/1000, Chemicon, CA, USA).
In all cases, membranes were washed three times in
PBS or TBS/Tween-20 and one wash in PBS or TBS
alone, immunolabeled protein bands were detected by
using HRP-conjugated anti-rabbit, anti-goat, or anti-
mouse antibody (1 : 5000, Santa Cruz Biotechnology,
CA, USA) following an enhanced chemiluminescence
system (ECL, GE Healthcare Bioscience, UK), and
autoradiographic exposure to Hyperfilm ECL (GE
Healthcare Bioscience, UK). Signals quantification
was performed using the Quantity OneTM software
v.4.6.3 (Bio-Rad, CA, USA). When-Actin or GSK3
where used as loading control, target and control
antibodies where analyzed from the same blot after
removing the antibody with stripping solution [Reblot
Plus Strong (Millipore, MA, USA)].
Immunoprecipitation and mitochondrial fraction
isolation
Immunoprecipitation was done according to the
catch and release reversible immunoprecipitation sys-
tem protocol (Upstate, NY, USA). Briefly, 100g of
hipocampal homogenates were added to the antibody
capture affinity ligand and the specific VDAC1 anti-
body and incubated in a catch and release spin column
at room temperature for 1 h under continuous shaking.
The column was then washed three times with the wash
buffer (10% Nonidet P-40, 2.5% deoxycholic acid,
150 mM imidazole, pH 7.4). The immunoprecipitate
was then eluted with Tris-based immunoprecipitation
elution buffer and analyzed by Western blotting as
above described.
For isolation of an enriched mitochondrial frac-
tion from hippocampus, a mitochondria isolation kit
(MITO-ISO1, Sigma, MO, USA) was used as recom-
mended by the manufacturer.
Tissue processing for immunohistochemistry
Under xylazine/ketamine anesthesia, animals were
perfused transcardially with saline and 4% para-
formaldehyde in phosphate buffer (PB). After per-
fusion, brains were removed, post-fixed in the same
fixative solution for 1 h at room temperature and cry-
oprotected in 30% sucrose solution in PB overnight
at 4.0◦C. Microtome sections (30m-thick) were cut
coronally through the entire hippocampus, collected
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free-floating and stored in 30% ethylene glycol, 30%
glycerol, and 0.1 M PB at –20◦C until processed.
Immunohistochemistry
Five free floating tissue sections comprising the
hippocampal formation of three animals per group
were processed for immunohistochemistry. Brain sec-
tions were washed (3 × 10 min) with phosphate buffer
saline 0.125 M, pH 7.4 (PBS) and incubated in block-
ing solution (PBS containing 1% Triton X-100, 0.5%
BSA) for 2 h at room temperature. Sections were incu-
bated overnight at 4◦C with the anti VDAC1 antibody
(Santa Cruz Biotechnology Inc., CA, USA) diluted
1 : 1000 in blocking solution, washed with PBS, and
incubated with the secondary antibody (Alexa Fluor
488 anti goat, Molecular Probes, OR, USA) diluted
1.200 in blocking solution. After washing with PBS
(3 × 10 min), sections were rinsed in 0.5M To-Pro-
3 (Invitrogen, OR, USA), air dried for 24 h, and
cover-slipped with immu-mount (Thermo Scientific,
PE, USA). To ensure comparable immunostaining,
sections were processed together under identical con-
ditions. For the assessment of non-specific primary
immunostaining, some sections from each experimen-
tal group were incubated without the primary antibody;
in this case no immunostaining was observed. Fluores-
cence signals were detected with confocal microscope
LSM 510 Meta (Carl Zeiss, Germany); objective Plan-
neofluar 20×/0.5. Images were captured at the level of
maximum fluorescence.
Determination of Aβ levels
A42 levels were determined by using a sensitive
sandwich ELISA kit from Biosource (Camarillo, CA,
USA) following the protocol described in [25].
RESULTS
Identiﬁcation of VDAC1 using a proteomics
approach as an upregulated protein
in the hippocampus of Tg2576 mice
Hippocampal proteins derived from 16-month-old
Tg2576 or WT mice were separated by means of 2-D
PAGE gels and analyzed on a MALDI-time-of-flight
(TOF) GL-REF mass spectrometer. Data processing
was performed with MASSLYNS. By quantitative
and statistical analyses, a total of 87 visualized pro-
tein spots were differentially expressed between the
two groups. These differentially expressed spots were
then excised and subjected to in-gel tryptic digestion
and identification by MALDI-TOF MS followed by
peptide mass fingerprinting. Among the 87 differen-
tially expressed proteins (not shown), VDAC1 (NCBI
identification number: gi|10720404gi| and accession
number: Q60932) was identified as that having the
greatest magnitude of change, 4.3-fold increase in
Tg2576 mice versus WT controls (Fig. 1).
Age-dependent increase of VDAC1 protein levels
in the hippocampus of Tg2576 mice
VDAC1 protein levels were analyzed by western-
blot in Tg2576 mice, which display significant A
production since 6–7 months and exhibit amyloid
plaques at 10–12 months (Fig. 2C) [6, 8]. VDAC1
protein levels in extracts from hippocampus of 7 and
12-month-old Tg2576 mice were determined and com-
pared with those in strain- and age-matched wild
type N-Tg controls (Fig. 2A). In 7 month-old ani-
mals there was a significant increase in VDAC1,
25%, and in 12 month-old animals, this increase was
much more marked, 98%, compared with N-Tg con-
trols. VDAC1 levels were also analyzed in another
amyloidogenic transgenic model of AD, J20 line,
with brain overexpression of human APP harbor-
ing both Swedish and Indiana fAD mutations, and
with marked A brain accumulation by the age of
4 months (Fig. 2C) [16]. Seven month-old J20 mice
displayed a significant elevation of VDAC1 in hip-
pocampal homogenates (Fig. 2B) thus confirming that
VDAC1 levels were increased in transgenic amyloido-
genic models of AD. VDAC1 immunoreactivity in
Fig. 1. Differential VDAC1 protein expression in the hippocampus
of 16 month-old Tg2576 mice. Portion of a Coomassie-stained 2-
D-gel from the hippocampus of Tg2576 (A) and non transgenic (B)
age-matched mice. Quantitative intensity analysis of three indepen-
dent experiments was performed to determine differential protein
expression. Differentially expressed proteins were identified by
MALDI-TOF MS followed by peptide mass fingerprinting. VDAC1
was increased by 4.3-fold (p < 0.05) related to non transgenic mice.
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Fig. 2. VDAC1 levels in Tg2576 and J20 mice. Hippocampal homogenates from 7 month-old Tg2576 and J20 mice, 12 month-old Tg2576
mice, or age-matched control mice (N-Tg) were analyzed by Western blot. A) VDAC levels were significantly increased in 7 (25%) and 12
(98%) month old Tg2576 mice (**p < 0.005 vs. N-Tg, Student’s t test). B) The J20 transgenic line also showed a 66% increase in VDAC
levels (*p < 0.05 vs. N-Tg, Student’s t test). C) Levels of A42 determined by ELISA. Bars represent the fold change of VDAC1/-actin ratio
(mean ± SEM) relative to N-Tg after the densitometric analysis of four different animals per group.
brain tissue was markedly increased in both amyloido-
genic lines, primarily in the pyramidal cells in CA1
hippocampus subfield (Fig. 3) but also in the cere-
bral cortex (not shown). Interestingly, the expression of
VDAC1 in the hippocampus of non transgenic animals
was very scarce. Overall, the results provide conver-
gent evidence of a strong correlation between high A
levels and increased levels of VDAC1.
Increase of VDAC1 in postmortem brain tissue
from AD patients
The levels of VDAC1 were also determined in sam-
ples from human brain tissue. Due to the scarcity of
hippocampal samples from AD patients, frontal cere-
bral cortex was used. It should be noted that, in AD,
extracellular amyloid plaques first appear in the frontal
cortex and not in the limbic system [26]. Brain tis-
sue was obtained from five patients of AD (Braak
stage V–VI) and from four control individuals with
no history of neurological or psychiatric illness. A sig-
nificant increase of VDAC1 protein was found in the
frontal cortex of AD patients (Fig. 4). Despite marked
interindividual differences, VDAC1 levels were signif-
icantly increased (55%) in AD patients related to non
demented controls.
In vitro induction of VDAC1 protein expression
by Aβ oligomers
Although the amyloid hypothesis states that central
nervous system build-up of A peptide is neurotoxic
and triggers the pathological cascade [27], neurotox-
icity of A has been more recently attributed to its
fibrillar forms referred to as ADDLs [28]. To check
whether VDAC1 expression was affected by A, SH-
SY5Y neuroblastoma cells were incubated with 5M
ADDLs and VDAC1 levels quantified in cell extracts
M. Cuadrado-Tejedor et al. / VDAC1 in Alzheimer’s Disease 201
A B
C D
E F
Fig. 3. VDAC1 immunoreactivity in hippocampal CA1 subfield.
Representative confocal microscopy images of VDAC labeling in
sections from 12 month-old non transgenic (A), Tg2576 (C) and 10
month-old J20 mice (E). Cell nuclei were labeled with Topro 3 (B,
D, and F). As indicated by the arrows, CA1 can be easily identified
by the VDAC immunostaining in both transgenic lines (C and E)
whereas in non transgenic control CA1 is not defined by the VDAC
immunoreactivity (A) (n = 4 animals per group, scale bar = 50m).
by Western blotting. As depicted on Fig. 5B, after 24 h
of ADDLs incubation, cellular homogenates showed
a significant increase in VDAC1 levels. A time course
experiment revealed that as early as at 2 h and up to
24 h treatment with 5M ADDL led to a sustained
increase in VDAC1 expression levels (Fig. 5C).
Enhanced VDAC1 phosphorylation and decreased
hexoquinase in the hippocampus of Tg2576 mice
Activation of GSK3 disrupts the binding of
HXK to mitochondria by phosphorylating VDAC1
and potentiates chemical-induced cytotoxicity [14].
To analyze its phosphorylation state, VDAC1 was
immunoprecipitated from hippocampal extracts from
12 month-old Tg2576 or non transgenic age-matched
mice, and immunoblotting was performed using a
phosphothreonine-reactive antibody. As shown in
Fig. 4. VDAC1 protein levels quantified by Western blot in tissue
lysates from the frontal cortex of AD patients (Braak stage V–VI,
n = 5), and the corresponding non demented controls (n = 4). AD
samples show a 1.6 fold change in VDAC levels (*p < 0.05, Stu-
dent’s t test). Bars represent the fold change of VDAC1/-actin ratio
(mean ± SEM) relative to controls after the densitometric analysis
of each individual determination.
A
C
B
Fig. 5. ADDLs induce VDAC1 overexpresion in SH-SY5Y neu-
roblastoma cells. A) Western blot of ADDL preparation using 6E10
antibody (amino acids 1–17 of Apeptide). B) Cultures of SH-SY5Y
neuroblastoma cells were incubated in presence of 5M ADDLs
for 24 h. Bars represent the fold change of VDAC1/-actin ratio
(mean ± SEM) relative to control after the densitometric analysis
of four different cell culture determinations (*p < 0.05, Student’s t
test). C) Time course analysis of VDAC1 levels after incubation of
SH-SY5Y neuroblastoma cells with 5M ADDL for the indicated
period of time.
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Fig. 6. Phosphothreonine-VDAC1 (phospho Thr-VDAC1) is increased in Tg 2576 and prevents the VDAC-HXK I interaction. A) Hippocampal
homogenates were immunoprecipitated with anti-VDAC1 antibody and immunoprecipitates blotted and probed with an anti-phosphothreonine-
reactive antibody or with an anti-VDAC1 antibody as a control of loading. Phosphorylated VDAC1 levels were significantly increased in
Tg2576 related to non transgenic age matched controls (N-Tg) (**p < 0.005, Student’s t test). B) Mitochondrial HXK I was determined by
immunoblotting mitochondrial homogenates with anti-HXK I antibody. A significantly lower amount in mitochondrial HXKI was found in
Tg2576 mice related to N-Tg (*p < 0.05, Student’s t test). C) Hippocampal homogenates were blotted and incubated with anti-pAkt (Ser473,
active form) and anti-pGSK3 (Ser9, inactive form) antibodies. -Actin and total GSK3were used as a control of charge for pAkt and pGSK3
respectively. Tg2576 mice showed a significant decrease in Akt activity (*p < 0.05, Student’s t test) and an increase in GSK3 activity (*p < 0.05,
Student’s t test), one of the VDAC phosphorylating kinase. Bars represent the fold change of represented ratios (mean ± SEM) relative to N-Tg
after the densitometric analysis of four different determinations.
Fig. 6A, there was a significant elevation in the lev-
els of threonine-phosphorylated VDAC1 in samples
from Tg2576 mice when compared with those from
non transgenic mice. Phosphorylation of VDAC and
the VDAC-HXK interaction are important factors for
apoptosis. To determine if VDAC phosphorylation cor-
relates with an altered balance of the VDAC : HXK
ratio, mitochondrial HXK was determined and found
to be significantly decreased in hippocampal extracts
from Tg2576 animals (Fig. 6A).
Deactivation of Akt and activation of GSK3β
in AD models
To investigate whether the Akt/GSK3 signaling
pathway could be involved in the increase in VDAC1
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Fig. 7. A 1-42 oligomers (ADDL) induce Akt inhibition and GSK3
activation in SH-SY5Y neuroblastoma cells. Cultures of SH-SY5Y
neuroblastoma cells were incubated in presence of 5M ADDLs
for 24 h. ADDL treated cells showed a significant decrease in active
Akt (pAKT-Ser473) (*p < 0.05, Student’s t test) and an increase in
active GSK3 (pGSK3-Ser9) (*p < 0.05, Student’s t test). Bars rep-
resent the fold change of represented ratios (mean ± SEM) relative
to non treated cells (control) after the densitometric analysis of four
different determinations.
phosphorylation shown in the hippocampus of Tg2576
mice, we analyzed the levels of pSer473-Akt (active
form) and pSer9-GSK3 (inactive form). VDAC1 has
an epitope that may be phosphorylated by GSK3 [14].
Compared with control mice, Tg2576 mice showed
a significant decline in pAkt levels averaging 49%,
and a concomitant decline, 73%, in the levels of
the inactive GSK3 form (Fig. 6B). To test whether
ADDLs addition to cell cultures affected the activa-
tion state of Akt and GSK3, levels of phospho-Ser473
Akt and phospho-Ser9 GSK3 were determined in
homogenates of SH-SY5Y cells preincubated with
5M ADDL. Western blots (Fig. 7) showed that
ADDLs reduced pSer473-Akt, with the consequent
reduced kinase activity of this protein, and also reduced
the amount of its downstream target pSer9-GSK3,
which would result in an increase in GSK3 kinase
activity.
Data obtained with amyloidogenic AD animal mod-
els and cultured neural cells indicate that A may be
responsible of an Akt- and GSK3-mediated increase
in phospho-VDAC1, more prone than the dephospho-
rylated form to induce the release of pro-apoptotic
factors [29].
DISCUSSION
Mitochondria are key players in apoptotic processes
underlying neuronal death in neurodegenerative dis-
eases. VDAC, as mitochondrial porin also found in
the neuronal membrane (pl-VDAC), is related to redox
homeostasis and apoptosis. Structure of mitochondria
and expression of mitochondrial proteins is altered
in AD [30]. Whether mitochondrial alterations are
the result of impaired turnover and removal of dam-
aged mitochondria, or damaged mitochondria at the
dystrophic neurites are the consequence of altered
expression and function of mitochondrial proteins is
not known. We here report an increase in VDAC1
protein expression in transgenic mice expressing high
levels of A and also in postmortem brain tissue
from AD patients at an advanced stage of the disease.
Addition of A oligomers (ADDLs) to cell cultures
increased VDAC1 levels supporting a role of A in
VDAC1 expression. A also appears to promote phos-
phorylation of VDAC1, which would subsequently
facilitate the leakage of mitochondrial proapoptotic
molecules, suggesting a contribution of VDAC1 to the
neurotoxic effects of A.
Although the exact cause of AD is still a mat-
ter of considerable debate [31], the amyloid cascade
hypothesis has provided a useful framework for the
research on this neurodegenerative disease for nearly
20 years [27]. Accordingly, an increased production or
decreased clearance of A peptide would be one of the
main causes of the disease. To confirm this hypothesis
transgenic mouse producing high levels of A are a
suitable model. In the present report, it is shown that
VDAC1 protein levels increased in the hippocampus
of Tg2576 mice, the increase being apparently related
to A production. The increase in VDAC1 levels was
already evident at the age of 7 months, when A also
starts to be significantly produced [8]. Reinforcing
the argument, J20 mice, another transgenic line with
higher A brain levels than Tg2576 mice [16], dis-
played a significant elevation of VDAC in hippocampal
homogenates from 7 month-old animals (see Fig. 2B),
thus supporting a causal link for A on VDAC increase
in AD mice models. It should be noted that the results
of Western-blot studies were confirmed by immunohis-
tochemical analysis showing that both Tg2576 and J20
mice displayed a marked rise in VDAC1 immunoreac-
tivity in the CA1 subfield of the hippocampus, a brain
region that is known to be selectively vulnerable in
human AD brains. High levels of VDAC were also
found in postmortem brain samples from AD patients
thus confirming that the finding was not restricted to
animal models.
ADDLs are soluble A oligomers whose in vivo
administration more strongly correlates with memory
impairment than that of monomeric forms [32]. In
Tg2576 mice, spatial memory impairment coincides
with the appearance of A soluble oligomers leading
to the hypothesis that A oligomers are more toxic than
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the monomer [7, 32]. These nonfibrillar assemblies of
A have been found also in brain extracts from AD
patients [33]. Oligomer toxicity may be related to alter-
ations in the Akt/GSK3 cascade and in fact ADDLs
promoted VDAC1 overexpression in neuroblastoma
cell cultures which was paralleled with a decrease of
Akt activity and with an increase in GSK3 activity.
VDAC1 possesses a GSK3 phosphorylation consen-
sus motif at amino acids 51 to 55. Mutation of VDAC
Thr51 prevents the ability of GSK3 to phosphory-
late it [14]. The kinase Akt regulates GSK3 activity
by phosphorylation at Ser9. Accordingly, we found
decreased levels of active Akt (pSer473-Akt) and also
decreased levels of inactive GSK3 (pSer9-GSK3)
in the hippocampus of AD mice models. Overall, it
seems that phosphorylation of VDAC1 in hippocam-
pal neurons could be, at least in part, performed by
GSK3.
In the hippocampus of transgenic mice, phosphory-
lated VDAC1 was the predominant form. Phosphory-
lation of the protein prevents its interaction with anti-
apoptotic proteins, such as HXK, and favors the release
of pro-apoptotic factors. VDAC1 is supposed to be
an essential player in apoptosis [34]. Overexpression
of human and murine VDAC1 induces apoptotic cell
death, regardless of the cell type [35–37]. There are
two possible mechanisms underlying VDAC1 role in
apoptosis. According to the first one, VDAC1 overex-
pression stimulates its oligomerization facilitating the
release of mitochondrial apoptogenic proteins such as
cytochrome c, the activator of caspases Smac/Diablo or
the apoptosis-inducing factor (AIF) [38]. The second
mechanism is related with its interaction with HXK
since the interaction favors a close state, whereas the
release of HXK promotes an open state that is more
prone to the release of mitochondrial pro-apoptotic
factors. VDAC1 function in mitochondrial transport is
regulated via interaction with associated proteins such
as members of the Bcl2 family and HXK. Strong evi-
dence supports VDAC-HXK interaction [35, 37, 39]
and the effect of this interaction on apoptosis (reviewed
in [34]). Conformational changes due to phospho-
rylation of VDAC1 is one of the mechanisms that
provoke the disruption of the VDAC-HXK interaction
in mitochondria [14]. In fact, when VDAC1 is phos-
phorylated on the putative GSK3 epitope, i.e., Thr51,
HXK is unable to interact with VDAC1, thus dissoci-
ating from the mitochondria. In the present report, it
was shown that the hippocampus from 12 month-old
Tg2576 mice had increased levels of pThr-VDAC1
coincident with lower HXK levels. Targeted disrup-
tion of mitochondria-HXK interaction or exposure to
proapoptotic stimuli that promote rapid dissociation of
HXK from mitochondria potently induce cytochrome
c release and apoptosis [29].
Taken together, our results indicate that VDAC1
overexpression could make hippocampal neurons more
sensitive to death. One of the major consequences
of GSK3 activation in AD is the hyperphosphory-
lation of the tau protein, which leads to cytoskeletal
destabilization and synapse dysfunction. Our data also
implicate this kinase in the neurodegenerative cascade
through the disruption of HXK-VDAC interaction by
VDAC1 phosphorylation. As apoptotic cell death has
been shown to represent the terminal process in some
neurodegenerative diseases such as AD, agents that
maintain the homeostasis of VDAC1 may offer new
and effective means of treating the disease. Modula-
tion of VDAC1 activity and/or phosphorylation may
therefore be considered as a potential therapeutic tar-
get addressed at reducing the release of mitochondrial
proapoptotic factors that impact into the viability of
hippocampal neurons.
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